Breztri becomes the first single-inhaler triple therapy for patients as young as 12 years ...

New reliever therapy reduced airway inflammation in adults with asthma using maintenance inhaled corticosteroids. Read more.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Inhalation of the long-acting selective beta ...

The FDA approved Breztri Aerosphere, a single-inhaler triple therapy, as a maintenance treatment for patients aged at least ...

Breztri Aerosphere is a single-inhaler fixed-dose triple therapy that combines budesonide, glycopyrrolate, and formoterol fumarate.

Use of β-2 adrenergic receptor (AR) agonists have been linked to a reduction in nocturnal hypoglycemia, but the efficacy of long-acting inhaled β-2 agonists for the treatment or prevention of ...

In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β 2-agonist may be an alternative to conventional treatment strategies. We conducted a 52-week, double-blind ...

A phase 4 study of formoterol fumarate showed similar safety performance as placebo in patients with moderate-to-severe chronic obstructive pulmonary disease, according to a recently published study.

This combination medication contains steroid and bronchodilator, prescribed for asthma in patients 12 years of age and older.

October 28, 2011 (Honolulu, Hawaii) — Two big clinical trials of mometasone furoate with formoterol (Dulera, Merck) found the combination safe and effective in improving the lung function of patients ...

A treatment currently approved for asthma, the beta-2 adrenergic receptor (AR) agonist formoterol, could help prevent hypoglycemia in patients with type 1 diabetes without causing hyperglycemia, a ...

The management of asthma has changed since the introduction of budesonide/formoterol (Symbicort ®) as both maintenance and reliever therapy (SMART). SMART and its effects on bronchial ...